Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS

Documenti analoghi

• An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes
  di: Angela X. Chen, et al.
  Pubblicazione: (2024)
• Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial
  di: Navdeep Tangri, et al.
  Pubblicazione: (2024)
• The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease
  di: Johannes David Smeijer, et al.
  Pubblicazione: (2024)
• Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial
  di: Massimo Nardone, et al.
  Pubblicazione: (2026)
• Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes
  di: Mohmmad Alghamdi, et al.
  Pubblicazione: (2025)